AVANIA
Avania , a leading global medical technology CRO, today announced its acquisition of IMARC, a highly respected medical device CRO headquartered in Strongsville, Ohio and providing service throughout the United States. IMARC brings more than two decades of full-service clinical research oversight to its clients, including monitoring, auditing, safety, data management, and training.
“At Avania, we are focused on building a high-quality, full-service specialist medical technology CRO with global reach,” said Avania CEO Sapna Hornyak. “We are delighted to welcome the IMARC team, with whom we have had the pleasure of collaborating for some time. They bring a great commitment to client service and outcomes and allow us to offer our clients additional depth and strength in the United States, complementing our existing global operations perfectly.”
IMARC clients will benefit from Avania’s extended international footprint, gaining access to the company’s extensive network in the EU and Australia. Additionally, Avania brings enhanced services to the combined companies — including biostatistics, strategic consulting, regulatory, and medical writing.
“Avania’s geographic and therapeutic area strengths make them the perfect strategic complement to IMARC,” said IMARC CEO Sandra Maddock. “Adding IMARC’s portfolio of capabilities to Avania’s will provide clients with a single-source provider of extensive, specialized medical device expertise combined with global reach.”
Covington Associates, a leading middle market investment bank, acted as exclusive financial advisor to IMARC in its sale to Avania.
About Avania
Avania is a leading, global full-service contract research organization focused on the management of clinical studies for medical devices, IVDs, biologics, and device-drug combination products internationally. Avania supports products from the first-in-human phase through the post-market phase with the same customized approach. When you need to advance your medical technology, it takes Avania. Avania’s vision is to be your trusted global partner in the evolution of your medical technology from innovation to commercialization to improving patient health and well-being.
About IMARC
IMARC assists clinical researchers pursuing FDA and worldwide approvals by preparing, educating, and guiding site teams from Day One to control the complex management of trials via cost-effective monitoring, auditing, and training services — resulting in the support, proof, and assurance they seek to overcome chaos caused by complexity while achieving compliance through consistency — based on competent, committed consultation and setting the highest standards for site outcomes and study partnerships.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210622005050/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Aurigene Oncology to Showcase Innovative A-PROX Platform at the AACR-NCI-EORTC International Conference 202522.10.2025 18:00:00 CEST | Press release
Aurigene Oncology Limited, a clinical-stage biopharmaceutical company developing novel therapies in oncology, today announced that it will present new data from its proprietary Targeted Protein Degradation (TPD) and Proximity Inducer Platform (A-PROX) at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics being held at the Hynes Convention Centerin Boston, MA, from October 22–26, 2025. Aurigene’s A-PROX platform integrates library screening, direct-to-biology chemistries, proprietary ternary complex assays, modelling algorithms, and structure-based design to accelerate the discovery and optimization of both protein degraders, molecular glues and proximity inducers. Through this integrated approach, Aurigene has advanced a strong pre-clinical portfolio of next-generation degraders, includinga SMARCA2-selective degrader, which recently received Investigational New Drug (IND) approval from the United States Food and Drug Administration (FDA); a pan-KRA
Visa Live Takes Flight with Benson Boone at the Rocket Garden22.10.2025 17:30:00 CEST | Press release
From le Louvre to the Launch Pad, Visa Live returns with another unforgettable music experience that puts fans at the center of the action. Prepare for lift-off this November as Visa presents another unforgettable cultural moment with Visa Live at the Rocket Gardenfeaturing global chart-topping sensation, Benson Boone on November 29. After the global success of Visa Live at le Louvre, the next chapter of the series lands at one of the world’s most iconic locations, the Rocket Garden at Kennedy Space Center Visitor Complex in Merritt Island, Florida. Headlined by Benson Boone, with a special guest to be announced, this event will be livestreamed on TikTok, inviting fans everywhere to join a night of music under the stars in a setting typically reserved for daylight exploration. “The Visa Live experience speaks to a fundamental truth in music: the space or environment in which the music is performed actually matters to both the artist and the audience,” said Frank Cooper III, Chief Marke
Stronghold's SHx Token Lists on Kraken Exchange22.10.2025 17:30:00 CEST | Press release
Driving the Next Wave of Fintech Innovation: Infrastructure Leader Expands Access to Utility Token Stronghold today announced that its SHx token is now available for trading on Kraken, one of the world's most trusted and secure cryptocurrency exchanges. Trading begins at 8:00 AM PST, marking SHx's first listing on a U.S.-based exchange and a significant expansion in accessibility for the token that powers payments, settlements, and community governance within the Stronghold ecosystem. "Listing on Kraken brings SHx to one of crypto's most sophisticated audiences, traders, and builders who understand utility-driven tokens. This is about liquidity, interoperability, and connecting our real-world payment infrastructure to a platform that shares our commitment to security, compliance, and transparency." — Tammy Camp, CEO & Co-Founder, Stronghold SHx operates on the Stellar blockchain as Stronghold's native utility token, enabling ecosystem governance, DeFi-based financing, and value transfe
Marjan and RAK Hospitality Holding Announce Landmark Merger to Shape The Future Of Ras Al Khaimah As A Global Destination for Lifestyle and Investment22.10.2025 17:17:00 CEST | Press release
Marjan, the master developer of freehold properties in Ras Al Khaimah, and RAK Hospitality Holding, the government-owned investment and development arm in the Emirate, have announced a landmark strategic merger to create a unified entity operating under Marjan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251022275206/en/ Marjan and RAK Hospitality Holding Announce Landmark Merger To Shape The Future Of Ras Al Khaimah As A Global Destination For Lifestyle And Investment (Photo: AETOSWire) This merger combines world-class hospitality expertise with visionary land development strategies to form a dynamic future-ready organization. Marjan will integrate real estate development, hospitality operations, and lifestyle experiences under one umbrella, positioning itself as one of the largest real estate developers in the UAE and the leading master developer in the Northern Emirates. Announcing the merger, His Highness Sheikh Ahmed
Venture Global Statement on CP2 Final Approval22.10.2025 16:33:00 CEST | Press release
The U.S. Department of Energy issued the final non-FTA export authorization for Venture Global’s CP2 facility in Cameron Parish, Louisiana. Venture Global CEO Mike Sabel issued the following statement: “Venture Global is grateful for the Trump Administration’s final approval of CP2, a critical project that will supply American allies with low-cost LNG for decades, support thousands of jobs and greatly benefit the U.S. balance of trade. The CP2 project construction is well underway and we look forward to continue advancing the project safely and quickly to bring new LNG to the global market at a record pace beginning in 2027.” About Venture Global Venture Global is an American producer and exporter of low-cost U.S. liquefied natural gas (LNG) with over 100 MTPA of capacity in production, construction, or development. Venture Global began producing LNG from its first facility in 2022 and is now one of the largest LNG exporters in the United States. The company’s vertically integrated bus
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom